An PPAP with antiproliferative properties; inhibits growth of NB69, Kelly, SK-N-AS, and LAN-1 neuroblastoma cells (IC50s = 3.1-6.3 μM); inhibits growth of Capan-1, AsPC-1, and MIA-PaCa-2 pancreatic cancer cells (IC50s = 4.5-5.0 μM, 72-hour treatment); activates the caspase cascade in a dose-dependent manner and inhibits cell cycle progression, increasing the proportion of cells in G0/G1 phase, in both neuroblastoma and pancreatic cancer cells; reduces tumor growth in an MIA-PaCa-2 mouse xenograft model (50 mg/kg, i.p., per day)